Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Return on Sales (2016 - 2025)

Historic Return on Sales for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to 0.12%.

  • Ani Pharmaceuticals' Return on Sales rose 2800.0% to 0.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.05%, marking a year-over-year increase of 600.0%. This contributed to the annual value of 0.03% for FY2024, which is 700.0% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Return on Sales is 0.12%, which was up 2800.0% from 0.04% recorded in Q2 2025.
  • Ani Pharmaceuticals' Return on Sales' 5-year high stood at 0.13% during Q1 2024, with a 5-year trough of 0.4% in Q4 2021.
  • Moreover, its 5-year median value for Return on Sales was 0.02% (2024), whereas its average is 0.06%.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Return on Sales tumbled by -3300bps in 2021, and later soared by 3500bps in 2022.
  • Ani Pharmaceuticals' Return on Sales (Quarter) stood at 0.4% in 2021, then soared by 89bps to 0.05% in 2022, then soared by 119bps to 0.01% in 2023, then crashed by -715bps to 0.05% in 2024, then soared by 317bps to 0.12% in 2025.
  • Its last three reported values are 0.12% in Q3 2025, 0.04% for Q2 2025, and 0.08% during Q1 2025.